TheranosticTrials.org

Clinical Trial · NCT02907073

Positron Emission Tomography (PET) Imaging Studies With NIS Reporter

Overview

The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).

Sponsor

Mayo Clinic

Phase

Phase 1/2

Contacts

Timothy R DeGrado (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02907073

Drug / Compound

Tetrafluoroborate

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules

Tetrafluoroborate

Isotope(s):
Target(s):
  • NET
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Willingness to provide all biological specimens as required by the protocol
  • Subjects must provide written informed consent.
  • * Four male and four female healthy volunteers, greater than 21 years of age.

Exclusion

  • Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:
  • unstable angina;
  • Have currently clinically significant cancer, neurologic, hepatic, renal, pulmonary, metabolic, or endocrine disturbances, especially thyroid disease;
  • Volunteers with any of the following are ineligible to enroll in this study:
  • cardiac surgery or myocardial infarction within the last 6 months;